vs
Side-by-side financial comparison of Essex Property Trust (ESS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Essex Property Trust is the larger business by last-quarter revenue ($479.6M vs $295.9M, roughly 1.6× Bio-Techne). Essex Property Trust runs the higher net margin — 17.9% vs 12.8%, a 5.0% gap on every dollar of revenue. On growth, Essex Property Trust posted the faster year-over-year revenue change (5.5% vs -6.4%). Over the past eight quarters, Essex Property Trust's revenue compounded faster (6.0% CAGR vs 4.2%).
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ESS vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $479.6M | $295.9M |
| Net Profit | $85.7M | $38.0M |
| Gross Margin | 70.0% | 64.6% |
| Operating Margin | 31.7% | 18.4% |
| Net Margin | 17.9% | 12.8% |
| Revenue YoY | 5.5% | -6.4% |
| Net Profit YoY | -71.6% | 68.3% |
| EPS (diluted) | $1.24 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $479.6M | $295.9M | ||
| Q3 25 | $473.3M | — | ||
| Q2 25 | $469.8M | $317.0M | ||
| Q1 25 | $464.6M | $316.2M | ||
| Q4 24 | $454.5M | $297.0M | ||
| Q3 24 | $450.7M | $289.5M | ||
| Q2 24 | $442.4M | $306.1M | ||
| Q1 24 | $426.9M | $303.4M |
| Q4 25 | $85.7M | $38.0M | ||
| Q3 25 | $172.7M | — | ||
| Q2 25 | $231.5M | $-17.7M | ||
| Q1 25 | $212.8M | $22.6M | ||
| Q4 24 | $301.7M | $34.9M | ||
| Q3 24 | $125.5M | $33.6M | ||
| Q2 24 | $99.0M | $40.6M | ||
| Q1 24 | $285.1M | $49.1M |
| Q4 25 | 70.0% | 64.6% | ||
| Q3 25 | 69.2% | — | ||
| Q2 25 | 70.7% | 62.7% | ||
| Q1 25 | 69.6% | 67.9% | ||
| Q4 24 | 70.0% | 65.3% | ||
| Q3 24 | 69.5% | 63.2% | ||
| Q2 24 | 70.8% | 66.4% | ||
| Q1 24 | 69.7% | 67.4% |
| Q4 25 | 31.7% | 18.4% | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 59.5% | -7.5% | ||
| Q1 25 | 55.3% | 12.2% | ||
| Q4 24 | 67.0% | 16.0% | ||
| Q3 24 | 28.6% | 13.8% | ||
| Q2 24 | 31.1% | 15.0% | ||
| Q1 24 | 31.0% | 22.1% |
| Q4 25 | 17.9% | 12.8% | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 49.3% | -5.6% | ||
| Q1 25 | 45.8% | 7.1% | ||
| Q4 24 | 66.4% | 11.7% | ||
| Q3 24 | 27.8% | 11.6% | ||
| Q2 24 | 22.4% | 13.3% | ||
| Q1 24 | 66.8% | 16.2% |
| Q4 25 | $1.24 | $0.24 | ||
| Q3 25 | $2.56 | — | ||
| Q2 25 | $3.44 | $-0.11 | ||
| Q1 25 | $3.16 | $0.14 | ||
| Q4 24 | $4.00 | $0.22 | ||
| Q3 24 | $1.84 | $0.21 | ||
| Q2 24 | $1.45 | $0.26 | ||
| Q1 24 | $4.25 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.2M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $5.5B | $2.0B |
| Total Assets | $13.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.2M | $172.9M | ||
| Q3 25 | $66.0M | — | ||
| Q2 25 | $58.7M | $162.2M | ||
| Q1 25 | $98.7M | $140.7M | ||
| Q4 24 | $66.8M | $177.5M | ||
| Q3 24 | $71.3M | $187.5M | ||
| Q2 24 | $55.2M | $152.9M | ||
| Q1 24 | $499.0M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | $346.0M | ||
| Q1 25 | $6.8B | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | $6.4B | $300.0M | ||
| Q2 24 | $6.2B | $319.0M | ||
| Q1 24 | $6.6B | $389.0M |
| Q4 25 | $5.5B | $2.0B | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $5.6B | $1.9B | ||
| Q1 25 | $5.6B | $2.0B | ||
| Q4 24 | $5.5B | $2.1B | ||
| Q3 24 | $5.4B | $2.1B | ||
| Q2 24 | $5.5B | $2.1B | ||
| Q1 24 | $5.5B | $2.0B |
| Q4 25 | $13.2B | $2.5B | ||
| Q3 25 | $13.2B | — | ||
| Q2 25 | $13.2B | $2.6B | ||
| Q1 25 | $13.2B | $2.6B | ||
| Q4 24 | $12.9B | $2.7B | ||
| Q3 24 | $12.6B | $2.7B | ||
| Q2 24 | $12.5B | $2.7B | ||
| Q1 24 | $12.9B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | 0.18× | ||
| Q1 25 | 1.22× | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | 1.18× | 0.14× | ||
| Q2 24 | 1.13× | 0.15× | ||
| Q1 24 | 1.19× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 12.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | — | ||
| Q3 25 | $342.6M | — | ||
| Q2 25 | $216.1M | $98.2M | ||
| Q1 25 | $281.5M | $41.1M | ||
| Q4 24 | $1.1B | $84.3M | ||
| Q3 24 | $316.2M | $63.9M | ||
| Q2 24 | $218.9M | $75.5M | ||
| Q1 24 | $314.9M | $81.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | 12.53× | — | ||
| Q3 25 | 1.98× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 1.32× | 1.82× | ||
| Q4 24 | 3.54× | 2.42× | ||
| Q3 24 | 2.52× | 1.90× | ||
| Q2 24 | 2.21× | 1.86× | ||
| Q1 24 | 1.10× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESS
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
